NASDAQ:PSTI - Pluristem Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.50
+0.30 (1.20%)

This chart shows the closing price for PSTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pluristem Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSTI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Pluristem Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $1.50.

This chart shows the closing price for PSTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Pluristem Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2021Alliance Global PartnersInitiated CoverageBuy$12.50Low
12/10/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00High
12/7/2020HC WainwrightReiterated RatingBuy$15.50 ➝ $9.00High
10/9/2020Dawson JamesReiterated RatingBuy$12.00Low
7/24/2020Jefferies Financial GroupBoost Price TargetBuy$12.00 ➝ $16.00Medium
6/19/2020Jefferies Financial GroupInitiated CoverageBuy$12.00High
5/15/2020Maxim GroupReiterated RatingBuy$12.00Low
5/14/2020HC WainwrightReiterated RatingBuy$15.50Medium
4/15/2020Dawson JamesReiterated RatingBuyHigh
4/14/2020Maxim GroupInitiated CoverageBuy$12.00High
4/8/2020Maxim GroupInitiated CoverageBuy$8.00High
3/31/2020Maxim GroupInitiated CoverageBuy$8.00Medium
3/18/2020Maxim GroupReiterated RatingBuy$8.00High
2/10/2020HC WainwrightReiterated RatingBuy$15.50Low
12/16/2019Dawson JamesInitiated CoverageBuy$12.00High
12/4/2019Maxim GroupReiterated RatingBuy$8.00Low
11/13/2019Maxim GroupReiterated RatingBuy$8.00High
11/13/2019HC WainwrightReiterated RatingBuy$15.50High
7/22/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ BuyLow
4/24/2019Maxim GroupReiterated RatingBuy$30.00Low
12/17/2018Maxim GroupSet Price TargetBuy$30.00Medium
12/17/2018HC WainwrightSet Price TargetBuy$40.00Medium
12/4/2018Maxim GroupSet Price TargetBuy$30.00High
11/28/2018Maxim GroupReiterated RatingBuy$30.00High
11/12/2018HC WainwrightSet Price TargetBuy$40.00Low
9/28/2018HC WainwrightReiterated RatingBuy$35.00Low
7/31/2018B. RileyInitiated CoverageBuy$45.00Low
5/11/2018HC WainwrightSet Price TargetBuy$40.00High
5/10/2018Maxim GroupSet Price TargetBuy$30.00Low
5/1/2018HC WainwrightSet Price TargetBuy$40.00Medium
4/30/2018Maxim GroupSet Price TargetBuy$30.00High
4/23/2018Maxim GroupReiterated RatingBuy$30.00Low
2/21/2018Maxim GroupSet Price TargetBuy$30.00Medium
1/16/2018HC WainwrightSet Price TargetBuy$40.00Medium
11/9/2017HC WainwrightReiterated RatingBuy$35.00N/A
11/1/2017Maxim GroupSet Price TargetBuy$30.00N/A
10/26/2017Maxim GroupSet Price TargetBuy$30.00N/A
10/19/2017Maxim GroupSet Price TargetBuy$20.00N/A
10/2/2017Maxim GroupSet Price TargetBuy$20.00Low
9/19/2017HC WainwrightReiterated RatingBuy$35.00Low
9/6/2017HC WainwrightReiterated RatingBuy$35.00Medium
9/5/2017Maxim GroupReiterated RatingBuy$20.00Medium
8/17/2017HC WainwrightSet Price TargetBuy$40.00Medium
8/16/2017Maxim GroupSet Price TargetBuy$20.00Medium
7/10/2017Maxim GroupSet Price TargetBuy$20.00High
6/19/2017Maxim GroupUpgradeHold ➝ Buy$20.00Low
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
1/24/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/23/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Pluristem Therapeutics logo
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Read More

Today's Range

Now: $1.50
Low: $1.46
High: $1.53

50 Day Range

MA: $1.80
Low: $1.37
High: $2.18

52 Week Range

Now: $1.50
Low: $1.31
High: $4.55

Volume

95,896 shs

Average Volume

972,262 shs

Market Capitalization

$48.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Pluristem Therapeutics?

The following Wall Street analysts have issued stock ratings on Pluristem Therapeutics in the last twelve months: StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for PSTI.

What is the current price target for Pluristem Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Pluristem Therapeutics in the last year.
View the latest price targets for PSTI.

What is the current consensus analyst rating for Pluristem Therapeutics?

Pluristem Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PSTI.

How do I contact Pluristem Therapeutics' investor relations team?

Pluristem Therapeutics' physical mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company's listed phone number is 972747107171 and its investor relations email address is [email protected] The official website for Pluristem Therapeutics is www.pluristem.com. Learn More about contacing Pluristem Therapeutics investor relations.